For 20 years, Agenus has been focused on building technologies and a product pipeline aimed at treating cancers and infection by helping the body’s immune system to target diseased cells with precision.We believe in the power of science. The body’s immune system is the single most effective tool we have to protect us from disease and help us fight disease when we get sick. At Agenus, we believe that by activating our body’s own natural mechanisms, using scientifically sound tools, we aim to help the body heal itself.
Our quest for science-focused solutions started in 1994. Nearly 20 years later, we remain committed to delivering on the promise of immunology to treat cancers and infectious diseases.
Agenus is gratified to be part of several important clinical development programs. We’re proud of the deep convictions and commitment we share with our growing circle of partners and collaborators to alleviate the burden of diseases and the burden of treatment.Pipeline
From advanced programs in late-stage development to our earlier clinical candidates, we continue to advance our groundbreaking technologies and product candidates closer to clinical practice, and closer to delivering on our promise of treating cancers and infectious diseases.
This website contains information regarding our future discovery and development efforts, our collaborations, our operating results and financial position, our business strategy, and other objectives for future operations. This information constitutes a forward-looking statement within the meaning of the Private Securities Litigation Reform Act of 1995. There are a number of risks and uncertainties that could cause our actual results to differ materially from those indicated by such forward-looking statements. These risks and uncertainties include those inherent in pharmaceutical research, such as adverse results in our drug discovery and clinical development processes, decisions made by the FDA and other regulatory authorities with respect to the development and commercialization of our products, and our ability to obtain, maintain and enforce proprietary rights for our products; our dependence on collaborative partners; our ability to obtain any necessary financing to conduct our planned activities, and other risk factors set forth in the filings that we make from time to time with the SEC. We disclaim any intention or obligation to update any forward-looking statements contained on this website, whether as a result of new information, future events or otherwise.